The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum
Open accessAbstract
Background Treatment guidelines for prediabetes primarily focus on glycemic control and lifestyle management. Few evidence-based cardiovascular and kidney risk-reduction strategies are available in this population. Objectives This study sought to characterize cardiovascular and kidney outcomes across the glycemic spectrum. Methods Among participants in the UK Biobank without prevalent type 1 diabetes, cardiovascular disease, or kidney disease, Cox models tested the association of glycemic exposures (type 2 diabetes [T2D], prediabetes, normoglycemia) with outcomes (atherosclerotic cardiovascular disease [ASCVD], chronic kidney disease [CKD], and heart failure), adjusting for demographic, lifestyle, and cardiometabolic risk factors. Results Among 336,709 individuals (mean age: 56.3 years, 55.4% female), 46,911 (13.9%) had prediabetes and 12,717 (3.8%) had T2D. Over median follow-up of 11.1 years, 6,476 (13.8%) individuals with prediabetes developed ≥1 incident outcome, of whom only 802 (12.4%) developed T2D prior to an incident diagnosis. Prediabetes and T2D were independently associated with ASCVD (prediabetes: adjusted HR [aHR]: 1.11; 95% CI: 1.08-1.15; P < 0.001; T2D: aHR: 1.44; 95% CI: 1.37-1.51; P < 0.001), CKD (prediabetes: aHR: 1.08; 95% CI: 1.02-1.14; P < 0.001; T2D: aHR: 1.57; 95% CI: 1.46-1.69; P < 0.001), and heart failure (prediabetes: aHR: 1.07; 95% CI: 1.01-1.14; P = 0.03; T2D: aHR: 1.25; 95% CI: 1.14-1.37; P < 0.001). Compared with hemoglobin A1c (HbA1c) <5.0%, covariate-adjusted risks increased significantly for ASCVD above HbA1c of 5.4%, CKD above HbA1c of 6.2%, and heart failure above HbA1c of 7.0%. Conclusions Prediabetes and T2D were associated with ASCVD, CKD, and heart failure, but a substantial gradient of risk was observed across HbA 1c levels below the threshold for diabetes. These findings highlight the need to design risk-reduction strategies across the glycemic spectrum.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These three comorbidities are frequently caused by metabolic risk, which is frequently driven by obesity and its associated risk factors, and the incidence of all three conditions rises with increasing A1C levels (17).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the incidence of all three conditions rises with increasing A1C levels (19).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The UK Biobank resource with deep phenotyping and genomic data
Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O’Connell, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0579-z · Cited by 8,876
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Fry, A., Littlejohns, T. J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins, R., & Allen, N. E. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx246 · Cited by 3,979
Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800256 · Cited by 1,475
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Kidney disease and increased mortality risk in type 2 diabetes
Afkarian, M., Sachs, M. C., Kestenbaum, B., Hirsch, I. B., Tuttle, K. R., Himmelfarb, J., & de Boer, I. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070718 · Cited by 1,298
Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014
Afkarian, M., Zelnick, L. R., Hall, Y. N., Heagerty, P. J., Tuttle, K., Weiss, N. S., & de Boer, I. H. (2016) · JAMA · doi:10.1001/jama.2016.10924 · Cited by 1,026
Elliott, P., Peakman, T. C., & Biobank, O. B. O. U. (2008) · International Journal of Epidemiology · doi:10.1093/ije/dym276 · Cited by 1,004
Khaw, K.-T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00006 · Cited by 974
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
Cai, X., Zhang, Y., Li, M., Wu, J. H., Mai, L., Li, J., Yang, Y., Hu, Y., & Huang, Y. (2020) · BMJ · doi:10.1136/bmj.m2297 · Cited by 749
Wheeler, D. C., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Toto, R. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30369-7 · Cited by 556
Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis
Bick, A. G., Pirruccello, J. P., Griffin, G. K., Gupta, N., Gabriel, S., Saleheen, D., Libby, P., Kathiresan, S., & Natarajan, P. (2019) · Circulation · doi:10.1161/circulationaha.119.044362 · Cited by 422
Self-citationPrevalence of prediabetes among adolescents and young adults in the United States, 2005-2016
Andes, L. J., Cheng, Y. J., Rolka, D. B., Gregg, E. W., & Imperatore, G. (2020) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2019.4498 · Cited by 380
Anker, S. D., Butler, J., Filippatos, G., Khan, M. S., Marx, N., Lam, C. S. P., Schnaidt, S., Ofstad, A. P., Brueckmann, M., Jamal, W., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051824 · Cited by 352
Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels
Bergenstal, R. M., Gal, R. L., Connor, C. G., Gubitosi-Klug, R., Kruger, D., Olson, B. A., Willi, S. M., Aleppo, G., Weinstock, R. S., Wood, J., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2596 · Cited by 306
Glycemic Control and Coronary Heart Disease Risk in Persons With and Without Diabetes
Selvin, E., Coresh, J., Golden, S. H., Brancati, F. L., Folsom, A. R., & Steffes, M. W. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.16.1910 · Cited by 285
McAllister, D. A., Read, S. H., Kerssens, J., Livingstone, S., McGurnaghan, S., Jhund, P., Petrie, J., Sattar, N., Fischbacher, C., Kristensen, S. L., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034986 · Cited by 244
Diabetes Mellitus, Prediabetes, and Incidence of Subclinical Myocardial Damage
Selvin, E., Lazo, M., Chen, Y., Shen, L., Rubin, J., McEvoy, J. W., Hoogeveen, R. C., Sharrett, A. R., Ballantyne, C. M., & Coresh, J. (2014) · Circulation · doi:10.1161/circulationaha.114.010815 · Cited by 231
3. Prevention or Delay of Type 2 Diabetes:Standards of Medical Care in Diabetes—2021
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc21-s003 · Cited by 217
Secular Changes in U.S. Prediabetes Prevalence Defined by Hemoglobin A1c and Fasting Plasma Glucose
Bullard, K. M., Saydah, S., Imperatore, G., Cowie, C. C., Gregg, E. W., Geiss, L. S., Cheng, Y. J., Rolka, D. B., Williams, D. E., & Caspersen, C. J. (2013) · Diabetes Care · doi:10.2337/dc12-2563 · Cited by 198
Risk of Progression to Diabetes Among Older Adults With Prediabetes
Rooney, M. R., Rawlings, A. M., Pankow, J. S., Echouffo-Tcheugui, J. B., Coresh, J., Sharrett, A. R., & Selvin, E. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.8774 · Cited by 184
Berg, D. D., Wiviott, S. D., Scirica, B. M., Gurmu, Y., Mosenzon, O., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042685 · Cited by 154
Shah, A. D., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades‐Rodríguez, M., Gale, C. P., Deanfield, J. E., Smeeth, L. L., Timmis, A., & Hemingway, H. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60401-9 · Cited by 144
Selvin, E., Yang, N., Steffes, M. W., Bash, L. D., Klein, R., Wong, T. Y., Astor, B. C., Sharrett, A. R., Brancati, F. L., & Coresh, J. (2010) · Diabetes · doi:10.2337/db10-1198 · Cited by 137
Glycated Hemoglobin, Prediabetes, and the Links to Cardiovascular Disease: Data From UK Biobank
Welsh, C. E., Welsh, P. I., Celis-Morales, C. A., Mark, P. B., Mackay, D., Ghouri, N., Ho, F. K. W., Ferguson, L. D., Brown, R., Lewsey, J., et al. (2019) · Diabetes Care · doi:10.2337/dc19-1683 · Cited by 112
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, R. R. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2000280 · Cited by 101
Skali, H., Shah, A. M., Gupta, D. K., Cheng, S. C., Claggett, B. L., Liu, J., Bello, N. A., Aguilar, D. A., Vardeny, O., Matsushita, K., et al. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.001990 · Cited by 92
de Jong, M., Woodward, M., & Peters, S. A. E. (2020) · Diabetes Care · doi:10.2337/dc19-2363 · Cited by 89
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-ad08 · Cited by 51
Honigberg, M. C., Chaffin, M. D., Aragam, K. G., Bhatt, D. L., Wood, M. J., Sarma, A. A., Scott, N. S., Peloso, G. M., & Natarajan, P. (2020) · Circulation · doi:10.1161/circulationaha.120.047936 · Cited by 38
Self-citationKim, H., Lee, J. B., Kim, S., Jo, M., Kim, E. H., Hwang, J. Y., Bae, S. J., Jung, C. H., Lee, W. J., Park, J., et al. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12343 · Cited by 16
The war on ‘prediabetes' could be a boon for pharma—but is it good medicine?
(2019) · AAAS Articles DO Group · doi:10.1126/science.aax2208 · Cited by 7
Cited by
Sorted by citations
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 339
Geng, T., Zhu, K., Lu, Q., Wan, Z., Chen, X., Liu, L., Pan, A., & Liu, G. (2023) · PLOS Medicine · doi:10.1371/journal.pmed.1004135 · Cited by 205
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 107
Zhang, N., Liu, X., Wang, L., Zhang, Y., Xiang, Y., Cai, J., Xu, H. Y., Xiao, X., & Zhao, X. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02347-3 · Cited by 98
Predicting and preventing heart failure in type 2 diabetes
Pandey, A., Khan, M. S., Patel, K. V., Bhatt, D. L., & Verma, S. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00128-6 · Cited by 84
Metadata
- Authors
- Honigberg, M. C., Zekavat, S. M., Pirruccello, J. P., Natarajan, P., & Vaduganathan, M.
- Affiliations
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Honigberg, Michael C.
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 78
- Issue
- 5
- Pages
- 453-464
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC8324525
- OpenAlex
- W3157902107
- Cited by
- 108
- References
- 34
- Citations by year
- 2026: 21 · 2025: 22 · 2024: 22 · 2023: 26 · 2022: 15 · 2021: 2
- FWCI
- 12.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Alexion Pharmaceuticals
- National Heart, Lung, and Blood Institute (R01HL142711, R01HL148050, R01HL148565, R01HL151283, T32HL094301-07)
- Baxter Healthcare Corporation
- Boehringer Ingelheim
- Cytokinetics
- Amgen
- Fondation Leducq (TNE-18CVD04)
- Massachusetts General Hospital
- Novartis
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- prediabetes, type 2 diabetes, HbA1c, glycemic control, atherosclerotic cardiovascular disease, chronic kidney disease, heart failure, cardiovascular risk, kidney disease risk, normoglycemia, UK Biobank, incident disease risk, cardiometabolic risk factors, lifestyle intervention, diabetes prevention, risk mitigation strategies
- MeSH terms
- Aged, Blood Glucose, Cardiovascular Diseases, Female, United Kingdom, Humans, Kidney Diseases, Male, Middle Aged, Prediabetic State, Biological Specimen Banks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
